Dawn E Quelle

List of Publications by Citations

45 papers	3,486 citations	19 h-index	51 g-index
51 ext. papers	3,811 ext. citations	7.6 avg, IF	4.64 L-index

#	Paper	IF	Citations
45	Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell*, **1997**, 91, 649-59	56.2	1400
44	Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. *Oncogene*, **1997**, 15, 203-11	9.2	465
43	Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. *Molecular and Cellular Biology*, **2005**, 25, 1258-71	4.8	248
42	The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. *Nature Medicine*, **2002**, 8, 743-50	50.5	224
41	p53 Acetylation: Regulation and Consequences. *Cancers*, **2014**, 7, 30-69	6.6	195
40	Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. *Cancer Research*, **2006**, 66, 2584-91	10.1	171
39	ARF function does not require p53 stabilization or Mdm2 relocalization. *Molecular and Cellular Biology*, **2002**, 22, 196-206	4.8	113
38	Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. *Molecular Cancer Research*, **2003**, 1, 195-206	6.6	82
37	Development and translational imaging of a TP53 porcine tumorigenesis model. *Journal of Clinical Investigation*, **2014**, 124, 4052-66	15.9	66
36	Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. *Journal of Immunology*, **2007**, 179, 2741-7	5.3	58
35	D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. *Cold Spring Harbor Symposia on Quantitative Biology*, **1994**, 59, 11-9	3.9	50
34	ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF. *Molecular and Cellular Biology*, **2005**, 25, 8024-36	4.8	38
33	A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. *Journal of Biological Chemistry*, **2007**, 282, 1322-33	5.4	30
32	Identification of Novel ARF Binding Proteins by Two-Hybrid Screening. *Cell Cycle*, **2006**, 5, 642-647	4.7	27
31	A porcine model of neurofibromatosis type 1 that mimics the human disease. *JCI Insight*, **2018**, 3,	9.9	26
30	Identification of novel ARF binding proteins by two-hybrid screening. *Cell Cycle*, **2006**, 5, 641-6	4.7	25
29	RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. *Cancer Research*, **2014**, 74, 6661-70	10.1	23

28	Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. *Molecular and Cellular Biology*, **2001**, 21, 6113-21	4.8	23
27	The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. *Molecular Cancer Research*, **2011**, 9, 867-77	6.6	21
26	Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. *Cell Cycle*, **2014**, 13, 1288-98	4.7	19
25	Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. *Experimental Cell Research*, **2009**, 315, 1326-35	4.2	19
24	RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. *Genes and Cancer*, **2013**, 4, 273-84	2.9	18
23	RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. *Journal of Clinical Investigation*, **2019**, 129, 1641-1653	15.9	17
22	RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors. *Clinical Cancer Research*, **2020**, 26, 2997-3011	12.9	17
21	Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. *Clinical Cancer Research*, **2020**, 26, 2011-2021	12.9	15
20	Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. *Journal of Histochemistry and Cytochemistry*, **2017**, 65, 607-618	3.4	14
19	Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. *Disease Markers*, **2018**, 2018, 3810108	3.2	11
18	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
17	RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. *PLoS ONE*, **2013**, 8, e80228	3.7	7
16	Longitudinal phenotype development in a minipig model of neurofibromatosis type 1. *Scientific Reports*, **2020**, 10, 5046	4.9	6
15	Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cells. *Scientific Reports*, **2017**, 7, 8157	4.9	6
14	Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. *Cancers*, **2021** , 13,	6.6	6
13	Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1. *Pain*, **2019**, 160, 2473-2486	8	6
12	PdgfrΕCre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis. *PLoS ONE*, **2020**, 15, e0236741	3.7	5
11	NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. *PLoS ONE*, **2014**, 9, e112126	3.7	4

10	Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2. *Hybridoma*, **2008**, 27, 159-66		4
9	Porcine cancer models for translational oncology. *Molecular and Cellular Oncology*, **2014**, 1, e969626	1.2	3
8	Phosphorylatable and epitope-tagged human erythropoietins: utility and purification of native baculovirus-derived forms. *Protein Expression and Purification*, **1992**, 3, 461-9	2	3
7	Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas. *Oncotarget*, **2021**, 12, 740-755	3.3	3
6	ARF sees Pdgfr through the miR. *Cell Cycle*, **2014**, 13, 1520-1	4.7	2
5	Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. *Scientific Reports*, **2021**, 11, 10252	4.9	2
4	RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo. *Biomedicines*, **2021**, 9,	4.8	2
3	Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. *Oncotarget*, **2021**, 12, 10-14	3.3	1
2	Validating indicators of CNS disorders in a swine model of neurological disease. *PLoS ONE*, **2020**, 15, e0228222	3.7	0
1	Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.. *Neuro-Oncology Advances*, **2022**, 4, vdac047	0.9	0